Different immunotherapeutics used for the treatment of multiple sclerosis (MS), i.e., teriflunomide (teri), mitoxantrone, and cladribine, are known substrates of ABCG2 [4–7]. The gene discussed is ABCG2; the disease is myeloid sarcoma.